To Newsroom
Oriola-KD Corporation's Interim Report for 1 January-31 March 2015
23.4.2015
Oriola-KD Corporation Stock Exchange Release 23 April 2015 at 8.30 a.m.
Oriola-KD Corporation's Interim Report for 1 January-31 March 2015
Financial performance January-March 2015
* Net sales increased by 3.0 per cent to EUR 411.3 (399.3) million
* EBITDA excluding non-recurring items decreased by 0.7 per cent to EUR 18.7
(18.8) million
* EBITDA was EUR 17.3 (18.2) million
* Operating profit excluding non-recurring items was EUR 13.1 (13.5) million
* Operating profit was EUR 11.7 (12.8) million
* Net cash flow from operations was EUR 13.3 (-25.8) million
* Profit for the period totalled EUR 7.4 (7.6) million and earnings per share
were EUR 0.05 (0.05)
Key figures 2015 2014 Change 2014
EUR million 1-3 1-3 % 1-12
----------------------------------------------------------------------------
Net sales 411.3 399.3 3.0 1,612.3
EBITDA excluding non-recurring items 18.7 18.8 -0.7 81.3
EBITDA 17.3 18.2 -5.0 87.2
----------------------------------------------------------------------------
Operating profit excluding non-recurring items 13.1 13.5 -2.5 59.1
Operating profit 11.7 12.8 -8.7 65.0
Operating profit % excluding non-recurring items 3.2 3.4 3.7
Operating profit % 2.9 3.2 4.0
Profit for the period 7.4 7.6 -2.7 46.5
----------------------------------------------------------------------------
Earnings per share, EUR 0.05 0.05 -6.5 0.29
Net cash flow from operating activities 13.3 -25.8 -10.8
Return on equity (ROE), % 24.3 3.6 23.7
Gearing, % 41.1 56.9 90.1
----------------------------------------------------------------------------
Outlook for 2015
Oriola-KD estimates its full-year net sales to remain at the 2014 level.
Operating profit excluding non-recurring items is estimated to increase from the
2014 level. Full-year net sales for continuing operations were EUR 1,612.3
million and operating profit excluding non-recurring items was EUR 59.1 million.
President and CEO Eero Hautaniemi's comments regarding the financial statements
release:
"Net sales of the Swedish businesses increased and operating profit excluding
non-recurring items remained at the level of the corresponding period. Net sales
of the Swedish wholesale business was supported by the new agreements with
pharmaceutical companies signed in 2014. Operating profit of the Swedish retail
business increased as a result of higher sales and effective cost control
measures, although new expensive prescription medicines with low margins lowered
the sales margin percentage. We continued to develop our product and pharmacy
portfolio during the first quarter. In accordance with our strategy we will open
an online pharmacy in Sweden during the second half of the year. The
depreciation of the Swedish krona from the corresponding period negatively
affected the euro denominated operating profit by approximately EUR 0.6 million.
Co-operation negotiations concerning Oriola-KD's personnel in Finland were
completed on 11 March 2015. The estimated annual cost savings will be
approximately EUR 2 million of which EUR 1.3 - 1.5 million are estimated to
realise in 2015. The related non-recurring costs recognised in the first quarter
were EUR 1.4 million.
In order to strengthen Oriola-KD's balance sheet and improve the equity ratio we
successfully completed EUR 75.6 million rights offering during the first
quarter. The offering was oversubscribed by approximately 146 per cent."
Oriola-KD Corporation's interim report 1 January-31 March 2015
The commentery of this financial statements release focuses on the January-March
2015 result. A comparison in accordance with the International Financial
Reporting Standards (IFRS) has been carried out on the figures for the
corresponding period in 2014, unless otherwise stated. The figures in this
interim report are unaudited. The results related to the Russian businesses sold
in December 2014 are presented as discontinued operations separately from the
results from continuing operations in January - March 2015 and comparative
period 2014 results have been revised to correspond to continuing operations.
The consolidated statement of financial position for the comparative period
2014 includes the assets and liabilities of discontinued operations. The
consolidated statement of cash flows for the comparative period 2014 includes
net cash flow of discontinued operations. The figures in the tables have been
rounded independently.
2015 2014 2014
Key Figures (1)) 1-3 1-3 1-12
-------------------------------------------------------------------------------
Goodwill, EUR million 253.7 365.5 250.9
Equity, EUR million 152.7 303.0 113.6
Interest-bearing debt, EUR million 199.9 260.5 193.9
Net interest-bearing debt, EUR million 62.7 172.5 102.4
Total assets, EUR million 961.6 1,389.2 874.0
Equity ratio, % 16.3 22.4 13.3
Return on equity (ROE), % 24.3 3.6 23.7
Return on capital employed (ROCE), % 15.0 5.0 14.4
Gearing, % 41.1 56.9 90.1
Net debt / rolling 12-month EBITDA from continuing
operations 0.7 3.0 1.2
Equity per share, EUR 0.84 2.00 0.75
Earnings per share, continuing operations, EUR 0.05 0.05 0.29
Earnings per share, incl. Discontinued operations,
EUR 0.04 0.02 -1.42
Average number of shares, 1000 pcs (2)) 158,504 151,142 151,130
Average number of personnel, continuing operations 2,301 2,335 2,377
Number of personnel at the end of the period,
continuing operations 2,256 2,350 2,356
Gross investments, continuing operations ,EUR
million 3.4 4.3 25.7
(1)) Comparative balance sheet items include discontinued operations unless
otherwise stated.
(2)) Treasury shares held by the company not included
Changes in the Group Structure in January-March 2015
There were no changes in the Group structure during the period.
The Group's net sales and result for January-March 2015
Oriola-KD's net sales increased by 3.0 per cent to EUR 411.3 (399.3) million and
operating profit excluding non-recurring items decreased by 2.5 per cent to EUR
13.1 (13.5) million. Operating profit was EUR 11.7 (12.8) million. The increase
of EUR 0.2 million in Group functions' expenses was mainly due to a change in
IFRS pension expense. Co-operation negotiations concerning Oriola-KD's personnel
in Finland were completed on 11 March 2015. The estimated annual cost savings
will be approximately EUR 2 million of which EUR 1.3 - 1.5 million are estimated
to realise in 2015. The related non-recurring costs recognised in the first
quarter were EUR 1.4 million. Non-recurring items of EUR 0.6 million reported
January-March 2014 relate to restructuring charges in Pharmaceutical Trade
Sweden.
Profit after financial items was EUR 9.8 (9.9) million and profit for the period
was EUR 7.4 (7.6) million. Oriola-KD's net financial expenses were EUR 2.0
(2.9) million. Income taxes for January-March 2015 were 2.3 (2.3) which
corresponds to effective tax rate of 23.8 (22.9) per cent. Earnings per share
were EUR 0.05 (0.05).
Reportable segments
Oriola-KD's reportable segments are Pharmaceutical Trade Sweden and
Pharmaceutical Trade Finland and Baltics. Oriola-KD has formed its reportable
segments by combining its operating segments. The Pharmaceutical Trade Sweden
reporting segment comprises the Swedish pharmaceutical retail and Swedish
pharmaceutical wholesale operating segments.The Pharmaceutical Trade Finland and
Baltics reporting segment comprises the Finnish pharmaceutical wholesale
business, the Consumer Health and the Pharmaceutical Trade Baltics operating
segments.
In December 2014 Oriola-KD sold its Russian businesses and as a result
classifies Russian businesses as discontinued operations.
Pharmaceutical Trade Sweden
Key Figures 2015 2014 Change 2014
EUR million 1-3 1-3 % 1-12
----------------------------------------------------------------------------
Net Sales 306.6 298.5 2.7 1,176.4
Retail business 186.4 186.6 -0.1 744.2
Wholesale business 202.8 195.5 3.7 761.2
----------------------------------------------------------------------------
Operating profit excluding non-recurring items 10.0 10.0 0.5 44.0
Retail business 7.6 7.4 2.6 33.8
Wholesale business 2.5 2.8 -10.0 10.4
----------------------------------------------------------------------------
Operating profit 10.0 9.4 7.0 50.5
Retail business 7.6 6.8 11.9 32.8
Wholesale business 2.5 2.8 -10.0 17.9
----------------------------------------------------------------------------
Operating profit % excluding non-recurring items 3.3 3.3 3.7
Retail business 4.1 4.0 4.5
Wholesale business 1.2 1.4 1.4
----------------------------------------------------------------------------
Operating profit % 3.3 3.1 4.3
Retail business 4.1 3.6 4.4
Wholesale business 1.2 1.4 2.4
----------------------------------------------------------------------------
Number of personnel at the end of period 1,757 1,816 1,792
Retail business 1,497 1,538 1,524
Wholesale business 260 278 268
----------------------------------------------------------------------------
January-March 2014
The net sales of Pharmaceutical Trade Sweden in January - March 2015 increased
by 2.7 per cent to EUR 306.6 (298.5) million, and on a constant currency basis,
net sales increased by 8.8 (13.7) per cent. Retail business net sales were EUR
186.4 (186.6) million, wholesale business net sales totalled EUR 202.8 (195.5)
million. Invoicing for the wholesale business was EUR 411.6 (371.7) million.
The Swedish retail business' EBITDA excluding non-recurring items was EUR 11.6
(11.2) million and EBITDA was EUR 11.6 (10.6) million in January - March 2015.
The EBITDA percentage excluding non-recurring items and the management fee for
the retail business was 6.5 (6.2) per cent.
The Swedish wholesale business' EBITDA was EUR 2.9 (3.4) million.
Pharmaceutical Trade Sweden's operating profit excluding non-recurring items
increased by 0.5 per cent to EUR 10.0 (10.0) million and operating profit
increased by 7.0 per cent and was EUR 10.0 (9.4) million. On a constant currency
basis operating profit excluding non-recurring items increased by 6.4 (229.4)
per cent. Operating profit excluding non-recurring items for the Swedish retail
business totalled EUR 7.6 (7.4) million and operating profit was EUR 7.6 (6.8)
million. Operating profit for the Swedish wholesale business was EUR 2.5 (2.8)
million.
Net sales of the Swedish retail business remained at the level of the
corresponding period. On a constant currency basis the net sales increased by
5.8 (47.5) per cent. Increased sales of the new expensive prescription medicine
with low margins negatively affected the relative profitability of the Swedish
retail business and decreased the relative share of OTC and traded goods from
the net sales to 25.7 (26.9) per cent. Pharmacy and product portfolios were
developed according to the plan. At the end of March 2015, Oriola-KD had a total
of 304 (300) pharmacies in Sweden. In accordance with the plan, Oriola-KD will
open an online pharmacy in Sweden during the second half of the year. Oriola-
KD's market share of the pharmaceutical retail market in January-March 2015 was
18.7 (19.1) per cent in January-March 2015 (source: Apoteksföreningen). Parallel
imports' share of the Swedish pharmaceutical market was approximately 10.3
(19.2) per cent in January-March (source: IMS Health).
The Swedish wholesale business' net sales increase was supported by new
agreements with pharmaceutical companies signed in 2014 and by the increased
sales of expensive RX products. On a constant currency basis the net sales
increased by 9.9 (11.4) per cent. The first quarter ramp up costs related to new
agreements with pharmaceutical companies were higher than expected. In addition
decreased share of sales of non-licence products with high margins, such as
Syprine, negatively affected profitability of the Swedish wholesale business
compared to corresponding period. Oriola-KD estimates that its share of the
Swedish pharmaceutical wholesale market was approximately 39 (39) per cent in
January-March 2015.
The pharmaceutical market in Sweden grew by 10.3 (0.3) per cent in Swedish krona
(source: IMS Health) and the retail market for OTC products and traded goods
grew by 10.9 (2.7) per cent in Swedish krona (source: Apoteksföreningen) in
January-March 2015. Based on Oriola-KD's estimate the number of pharmacies in
Sweden increased by one pharmacy in January-March 2015, at the end of March
there were 1,338 pharmacies in Sweden.
Pharmaceutical Trade Finland and Baltics
Key Figures 2015 2014 Change 2014
EUR million 1-3 1-3 % 1-12
--------------------------------------------------------------------------
Net Sales 104.7 100.8 3.9 435.9
Pharmaceutical wholesale in Finland 80.8 79.3 1.9 348.7
Pharmaceutical wholesale in Baltics 13.1 11.4 15.3 46.6
Consumer Health 10.9 10.2 6.7 40.9
--------------------------------------------------------------------------
Operating profit excluding non-recurring items 4.6 4.8 -3.9 19.6
--------------------------------------------------------------------------
Operating profit 3.7 4.8 -22.2 19.2
--------------------------------------------------------------------------
Operating profit % excluding non-recurring items 4.4 4.8 4.5
--------------------------------------------------------------------------
Operating profit % 3.6 4.8 4.4
--------------------------------------------------------------------------
Number of personnel at the end of period 462 493 523
--------------------------------------------------------------------------
January-March 2015
The net sales of Pharmaceutical Trade Finland and Baltics increased by 3.9 per
cent to EUR 104.7 (100.8) million. Operating profit excluding non-recurring
items decreased by 3.9 per cent to EUR 4.6 (4.8) million. Operating profit
decreased by 22.2 per cent to EUR 3.7 (4.8) million.
The net sales of the wholesale business in Finland was EUR 80.8 (79.3) million
and invoicing totalled EUR 249.4 (235.8) million. Net sales of the wholesale
business in the Baltic countries were EUR 13.1 (11.4) million. Net sales of the
Consumer Health business were EUR 10.9 (10.2) million.
The EBITDA excluding non-recurring items of Pharmaceutical Trade Finland and
Baltics was EUR 5.7 (5.7) million and EBITDA was EUR 4.8 (5.7) million.
In Finnish wholesale business Oriola-KD renewed agreement with Abbott Oy and
made new agreement with Biohit Corporation concerning distribution of the
Acetium products. Service sales to the pharmaceutical companies increased in
Finnish wholesale business. Orion's traded goods products moved over to
Oriolashop.fi from the beginning of September 2014 and as a result net sales of
the Oriolashop.fi online shop increased significantly. Out of the Consumer
Health brands, net sales of Avène and Gefilus increased in January - March
2015. As a result of tightened competitive environment, profitability of
Consumer Health business decreased from the corresponding period due to bigger
discounts.
The Finnish pharmaceutical market grew by 1.6 (3.1) per cent in January - March
2015 (source: IMS Express). Oriola-KD's share of the Finnish pharmaceutical
wholesale market was 45.8 (44.7) per cent in January - March 2015 (source: ATY).
Non-recurring items
A non-recurring item is an income or expense arising from non-recurring or rare
events. Gains or losses from the sale or discontinuation of business operations
or assets, gains or losses from restructuring business operations, and
impairment losses of goodwill and other non-current assets are recognised by
Oriola-KD as non-recurring items.
Non-recurring items included in Operating Profit 2015 2014 2014
EUR million 1-3 1-3 1-12
------------------------------------------------------------------
Pharmaceutical Trade Finland and Baltics
Restructuring costs -0.9 - -
Service award arrangement - - -0.5
Pharmaceutical Trade Sweden
Restructuring costs - -0.6 -1.0
Gain on sale of property - - 7.5
Group items
Restructuring costs -0.5 - -
Service award arrangement - - -0.1
------------------------------------------------------------------
Total -1.4 -0.6 5.9
------------------------------------------------------------------
Non-recurring items reported in Januray - March 2015 relate to restructuring
charges in Finnish pharmaceutical wholesale business, Consumer Health and Group
functions. Non-recurring items reported January-March 2014 relate to
restructuring charges in Pharmaceutical Trade Sweden.
Balance sheet, financing and cash flow
Oriola-KD's total assets at 31 March 2015 were EUR 961.6 (1,389.2) million. Cash
and cash equivalents totalled EUR 137.1 (88.0) million and equity was EUR 152.7
(303.0) million. The equity ratio was 16.3 (22.4) per cent and gearing was 41.1
(56.9) per cent. The comparative information includes discontinued operations.
During the first quarter of 2015 Oriola-KD completed a rights offering. From the
offering Oriola-KD raised gross proceeds of EUR 75.6 million and net proceeds of
EUR 74.0 million.
Oriola-KD decided to redeem its EUR 40 million hybrid bond issued on 20 February
2014 in its entirety together with accrued interest. The bond was redeemed in
accordance with its terms and conditions on 20 April 2015 with 103 per cent of
its nominal value. The nominal of the bond together with accrued interest, in
total EUR 41.5 million, is reported as short term interest-bearing debt at 31
March 2015.
Oriola-KD's goodwill of EUR 253.7 (365.5) million has been allocated in
impairment testing to the cash-generating units consisting of the Group's
operating segments. In Oriola-KD goodwill is tested annually, in accordance with
the timetable of its strategy and planning process. At the end of March 2015,
EUR 227.8 (236.5) millions of the goodwill was allocated to the Swedish
pharmaceutical retail business, EUR 25.7 (26.6) million to the Swedish
pharmaceutical wholesale business and EUR 0.2 (-) million to the Pharmaceutical
Trade Baltics.
At the end of March 2015, interest-bearing debt was EUR 199.9 (260.5) million of
which syndicated bank loans totalled EUR 83.1 (170.9) million, commercial papers
EUR 32.8 (40.6) million, advance payments from pharmacies EUR 23.0 (33.4)
million, a contingent consideration related to Medstop-acquisition EUR 15.1
(14.7) million and finance lease liabilities EUR 4.2 (0.9) million. Long-term
interest bearing-liabilities were EUR 79.3 (174.9) million and short-term
interest-bearing liabilities were EUR 120.6 (85.6) million. Interest-bearing net
debt was EUR 62.7 (172.5) million. The non-recourse trade receivables sales
programmes were continued in the Pharmaceutical Trade Sweden in January-March
2015. At the end of March 2015, a total of EUR 106.4 (72.6) million in trade
receivables had been sold.
Oriola-KD's committed long-term credit facility of EUR 100.0 million and EUR
55.8 million of short-term credit account limits with banks were unused at the
end of March 2015. Oriola-KD signed a financing agreement of approximately EUR
280 million during the second quarter of 2013.
Financial covenants contained 31 Mar 2015 30 Jun 2015 30 Sep 2015 31 Dec 2015
in the financing agreement
-------------------------------------------------------------------------------
Ratio between net debt and
rolling 12-month EBITDA 3.00 3.00 3.00 3.00
Gearing ratio 100 % 100 % 100 % 100 %
The financial covenants contained in the financing agreement are based on the
ratio between the Group's net debt and rolling 12-month EBITDA and gearing
ratio. The ratio between the Group's net debt and the 12-month rolling EBITDA
was 0.73 and the adjusted ratio in accordance with the terms and conditions of
the financing agreement, stood at 0.55, the covenant limit in the agreement
being 3.00.The gearing ratio was 41.1 per cent and the adjusted gearing ratio in
accordance with the terms and conditions of the financing agreement, stood at
31.2 per cent, the covenant limit in the agreement being 100 per cent.
Net cash flow from operations including discontinued operations in January-March
2015 was EUR 13.3 (-25.8) million, of which changes in working capital accounted
for EUR -0.5 (-32.5) million. Net cash flow from investing activities was EUR
-3.9 (-4.9) million.
Investments
Gross investments in January-March 2015 totalled EUR 3.4 (4.3) million and
consisted of investments related to the opening of new pharmacies, information
systems and improvements in logistics efficiency.
Personnel
At the end of March 2015, Oriola-KD had a payroll of 2,256 (2,350) employees,
22 (23) per cent of whom worked in Finland and the Baltics and 78 (77) per cent
in Sweden. Personnel numbers consist of members of staff in active employment.
Administration
Oriola-KD's Group Management Team:
* Eero Hautaniemi, President and CEO
* Sari Aitokallio, Interim CFO (from April 9, 2015)
* Lars Birkeland, Vice President, pharmaceutical retail, Sweden
* Jukka Mäkelä, Vice President, Development
* Teija Silver, Vice President, HR
* Kimmo Virtanen, Executive Vice President, pharmaceutical wholesale, Finland,
Sweden and the Baltics
* Tuomas Itkonen, CFO (until April 1, 2015)
Oriola-KD applies the Finnish Corporate Governance Code which was issued by the
Securities Market Association on 15 June 2010 and which entered into force on 1
October 2010, with the exception that the company's Nomination Committee may
also have members who are not members of the company's Board of Directors. The
purpose of this deviation from Recommendation 22 of the Corporate Governance
Code (Appointment of members to the committees) is to allow the election of
major shareholders in the company to the Nomination Committee and thus to ensure
that their opinions are heard well before the Annual General Meeting. The
Nomination Committee is a body established by the Board for the purpose of
preparing and presenting to the Board a recommendation for the proposal to be
put to the Annual General Meeting concerning the composition and remuneration of
the Board. The Corporate Governance Statement and the Remuneration Statement
for 2014 can be viewed on the company's website at: http://www.oriola-
kd.com/en/Corporate-Governance/.
Resolutions of the Annual General Meeting
The Annual General Meeting (AGM), held on 30 March 2015 adopted the financial
statements and discharged the members of the Board of Directors and the
President and CEO from liability for the financial year ending 31 December 2014.
The AGM resolved that no dividend shall be paid on the basis of the balance
sheet adopted for the financial year ending 31 December 2014.
The AGM confirmed that the Board of Directors is composed of eight members.
Current members of the Board of Directors Mr Jukka Alho, Mr Per Båtelson, Ms
Anja Korhonen, Mr Kuisma Niemelä and Mr Matti Rihko were re-elected to the Board
of Directors, and Ms Eva Nilsson Bågenholm, Mr Staffan Simberg and Mr Anssi
Vanjoki were elected new members of the Board of Directors. Mr Anssi Vanjoki was
elected Chairman of the Board of Directors.The AGM confirmed that the fee for
the term of office of the Chairman of the Board of Directors is EUR 48,400, the
fee for the term of office of the Vice Chairman of the Board of Directors and
for the Chairman of the Board's Audit Committee is EUR 30,250 and the fee for
the term of office of other members of the Board of Directors is EUR 24,200. Of
the annual fee, 60 per cent shall be paid in cash and 40 per cent shall be used
to acquire Oriola-KD Corporation's class B shares for the Board members on the
NASDAQ OMX Helsinki Stock Exchange within two weeks from the release of the
Interim Report 1 January - 31 March 2015 of the company. The Chairman of the
Board of Directors receives an attendance fee of EUR 1000 per meeting and the
other members EUR 500 per meeting. Attendance fees are correspondingly also paid
to the chairmen and members of Board and company committees. Travel expenses are
compensated in accordance with the travel policy of the company.
In its constitutive meeting, convening after the AGM, the Board of Directors of
Oriola-KD Corporation elected Mr Jukka Alho as Vice Chairman of the Board of
Directors. The Board appointed the following from among its members: Ms Anja
Korhonen (Chairman), Mr Kuisma Niemelä and Mr Staffan Simberg to the Board's
Audit Committee, and Mr Jukka Alho (Chairman), Mr Per Båtelson and Ms Eva
Nilsson Bågenholm and Mr Matti Rihko to the Board's Remuneration Committee.
The Board of Directors has assessed the independence of the members of the
Board, and determined that all members of the Board are independent of the
company and its major shareholders.
PricewaterhouseCoopers Oy, who has put forward authorised public accountant Mr
Kaj Wasenius as principal auditor, was elected as the auditor of the company.
The auditor's fees shall be paid according to invoice approved by the company.
The AGM authorised the Board of Directors to decide on a share issue against
payment in one or more issues. The authorisation comprises the right to issue
new shares or assign treasury shares held by the company. The authorisation
covers a maximum of 5,650,000 Class A shares and 12,500,000 Class B shares and
includes the right to derogate from the shareholders' pre-emptive subscription
right. Pursuant to the authorisation, shares held by the company as treasury
shares may also be sold through trading on a regulated market organised by
NASDAQ OMX Helsinki Ltd. The authorisation is in effect for a period of
eighteen months from the decision of the Annual General Meeting.
The AGM authorised the Board of Directors to decide on a share issue against
payment in one or more issues. The authorisation comprises the right to issue
new class B shares or assign class B treasury shares held by the company. The
authorisation covers a combined maximum of 18,000,000 class B shares of the
company and includes the right to derogate from the shareholders' pre-emptive
subscription right. Pursuant to the authorisation, class B shares held by the
Company as treasury shares may also be sold on regulated market organised by
NASDAQ OMX Helsinki Ltd. The authorisation is in effect for a period of eighteen
months from the decision of the Annual General Meeting.
The authorisation revokes all previous share issue authorisations given to the
Board of Directors apart from the authorisation given to the Board of Directors
by the Annual General Meeting held on 20 March 2013, pursuant to which the Board
of Directors may decide upon directed share issues against or without a payment
concerning no more than 1,715,000 class B shares in order to execute the share-
based incentive plan for the Oriola-KD Group's executives and the share savings
plan for the Oriola-KD Group's key personnel.
The AGM also authorised the Board of Directors to decide on repurchasing of the
company's own class B shares. The authorisation entitles the Board of Directors
to decide on the repurchase of no more than 18,000,000 of the company's own
class B shares in a proportion other than in which shares are owned by the
shareholders. The authorisation to repurchase own shares is in force for a
period of not more than eighteen months from the decision of the Annual General
Meeting. Shares may be repurchased to develop the company's capital structure,
to execute corporate transactions or other business arrangements, to finance
investments, to be used as a part of the company's incentive schemes or to be
otherwise relinquished, held by the company or cancelled.
Oriola-KD Corporation shares
Oriola-KD completed a rights offering in the first quarter of 2015. The
subscription period of the offering ended on 3 March 2015. In the offering
9,429,742 new A Shares and 20,798,643 new B Shared were subscribed. As a result,
the total number of shares of Oriola-KD increased to 181,486,213 shares. The
subscribtion price was EUR 2,50 per offered share. Oriola-KD raised gross
proceeds of EUR 75.6 million through the offering. Oriola-KD recognised gross
proceeds and the transaction costs less taxes, in total of EUR 74.0 million, in
the invested unrestricted equtity fund.
Trading volume of the Oriola-KD Corporation's class A and B shares in January-
March 2015:
January-March 2015 January-March 2014
Trading volume class A class B class A class B
------------------------------------------------------------------------------
Trading volume, million 1.2 15.5 3.4 8.5
Trading volume, EUR million 4.6 56.5 8.1 20.7
Highest price, EUR 4.15 4.10 2.85 2.78
Lowest price, EUR 3.11 3.05 2.25 2.13
Closing quotation, end of period, EUR 3.82 3.79 2.55 2.51
------------------------------------------------------------------------------
Oriola-KD Corporation's market capitalisation on 31 March 2015 was EUR 689.5
(381.5) million.
In the review period, the traded volume of Oriola-KD Corporation shares,
excluding treasury shares, corresponded to 10.6 (7.9) per cent of the total
number of shares. The traded volume of class A shares amounted to 2.5 (7.2) per
cent of the average stock, and that of class B shares, excluding treasury
shares, to 14.3 (8.2) per cent of the average stock.
At the end of March 2015, the company had a total of 181,486,213 (151,257,828)
shares, of which 56,578,452 (47,148,710) were class A shares and 124,907,761
(104,109,118) were class B shares. The company has 148,338 (115,902) treasury
shares (including treasury shares held by third-party service provider), all of
which are class B shares. They account for 0.08 (0.08) per cent of the company's
shares and 0.012 (0.011) per cent of the votes.
Under Article 3 of the Articles of Association, a shareholder may demand
conversion of class A shares into class B shares. During the period 1 January -
31 March 2015, no class A shares were converted into class B shares (0 shares).
On 19 December 2012, Oriola-KD Corporation's Board of Directors decided on a
share incentive scheme for the Group's senior management for the years
2013-2015. The scheme covers six persons. The company's Board of Directors will
determine the earnings criteria for the earning period and the targets to be set
for these at the start of each earning period. The bonus for the 2015 earning
period is based on the Oriola-KD Group's earnings per share (EPS) calculated
from the earnings excluding non-recurring items and taxes. The rewards to be
paid on the basis of the performance period 2015 will correspond to the value of
a maximum total of 1,010,000 Oriola-KD Corporation class B shares (also
including the proportion to be paid in cash), of which 625,483 Oriola-KD
Corporation class B shares (also including the proportion to be paid in cash)
have been allocated to the current participants.
The Board of Oriola-KD Corporation approved the terms and conditions of the key
employees' share savings plan on 28 May 2013. A total of about 37 key employees
are participating in the plan. The savings period started on 1 October 2013 and
end on 30 September 2014. In addition the Board of Oriola-KD Corporation
approved on 27 August 2014 the terms and conditions of the key employees' share
savings plan. A total of about 43 key employees are participating in the plan.
The savings period started on 1 October 2014 and end on 30 September 2015. For
both savings plans the maximum and minimum monthly savings amount to 10 and 2
per cent, respectively, of each participant's fixed gross monthly salary. The
accumulated savings will be used for purchasing Oriola-KD's class B shares for
the participants at market prices. About two years after the start of the
programme, the company will give the participants two class B shares for every
three shares purchased as part of the programme. The shares given to the
participants will be partially used for paying taxes. Oriola-KD Corporation has
an agreement with a third-party service provider concerning administration of
the share-based incentive program. At the end of the reporting period, the
amount of treasury shares held by the third-party service provider was 51,516
(23,850).
Liquidity guarantee
There is no liquidity guarantee in effect for the shares of Oriola-KD
Corporation.
Flagging announcements
No flagging announcements were received during the period.
Risks
Oriola-KD's Board of Directors has approved the company's risk management policy
in which the risk management operating model, principles, responsibilities and
reporting are specified. The Group's risk management seeks to identify, measure
and manage risks that may threaten Oriola-KD's operations and the achievement of
goals set. The roles and responsibilities relating to risk management have been
determined in the Group.
Oriola-KD's risks are classified as strategic, operational and financial. Risk
management is a key element of the strategic process, operational planning and
daily decision-making at Oriola-KD.
Oriola-KD has identified the following principal strategic and operational risks
in its business:
* Amendments to pharmaceutical market regulations, pricing of pharmaceuticals
and reimburesements may weaken Oriola-KD's net sales and profitability.
* In the Swedish retail business, the free establishment of pharmacies has led
to an increase in the number of pharmacies. The number of pharmacies may
continue to grow, which could further increase the fierce competition.
* Extra capacity ensuing from a change in the Swedish wholesale market will
intensify competition, which may weaken the profitability of operations. The
share of single channel distribution in the pharmaceutical wholesale market
may decline rapidly, which may weaken the profitability of operations and
lead to the restructuring of wholesale operations.
* Changes in share of parallel imports in Swedish pharmaceutical market may
affect profitability of the Swedish wholesale and retail businesses.
* Strategic development projects involve operational risks.
The main financial risks for Oriola-KD involve currency rate, liquidity,
interest rate and credit risks. Currency risk is the most significant financial
risks in Sweden, as any changes in the value of the Swedish krona will have an
impact on Oriola-KD's net sales, earnings and consolidated statement of
financial position.
Oriola-KD prepares goodwill impairment testing annually, in accordance with the
timetable of its strategy and planning process. Changes in cash flow forecasts
based on strategic plans, or in the discount rate or perpetuity growth rate, can
cause a goodwill write-off, which would weaken Oriola-KD's result.
Near-term risks and uncertainty factors
Oriola-KD's strategic development projects involve operational risks which may
have an effect on Oriola-KD's profitability.
Outlook
Oriola-KD's outlook for 2015 is based on external market forecasts, agreements
with pharmaceutical companies and pharmacies, and management assessments. During
the five-year period from 2013-2018, the Finnish pharmaceutical market is
expected to grow at an annual rate of 2.6 per cent and Swedish pharmaceutical
market is expected to change an average of 0 per cent per year in the local
currencies (source: IMS Health Prognosis 2014-2018, September 2014).
Outlook for 2015
Oriola-KD estimates its full-year net sales to remain at the 2014 level.
Operating profit excluding non-recurring items is estimated to increase from the
2014 level. Full-year net sales for continuing operations were EUR 1,612.3
million and operating profit excluding non-recurring items was EUR 59.1 million.
Events after the review period
Sari Aitokallio, Master of Laws (b. 1960) was appointed interim Chief Financial
Officer (CFO) of Oriola-KD Corporation and member of Oriola-KD Group's
Management Team as of 9 April 2015. Based on an agreement with the company
Tuomas Itkonen, CFO of Oriola-KD and a member of Oriola-KD's Group Management
Team left Oriola-KD on 1 April 2015.
Oriola-KD decided to redeem its EUR 40 million hybrid bond issued on 20 February
2014 in its entirety together with accrued interest. The bond was redeemed in
accordance with its terms and conditions on 20 April 2015 with 103 per cent of
its nominal value. The redemption price together with accrued interest was EUR
41.7 million.
Next interim report
Oriola-KD Corporation will publish its results for the second quarter of 2015 on
17 July 2015 at about 8.30 am.
Oriola-KD's Interim Report January - March 2015
Consolidated Statement of
Comprehensive Income (IFRS), 2015 2014 2014
EUR million 1-3 1-3 1- 12
Revised (1) )
-------------------------------------------------------------------------------
Continuing operations
Net sales 411.3 399.3 1,612.3
Other operating income 3.1 2.5 21.0
Cost of goods sold -331.9 -318.0 -1,287.9
Employee benefit expenses -37.8 -37.5 -143.8
Other operating expenses -27.4 -28.1 -114.5
-------------------------------------------------------------------------------
Gross profit 17.3 18.2 87.2
Depreciation and impairment -5.6 -5.4 -22.2
-------------------------------------------------------------------------------
Operating profit 11.7 12.8 65.0
Financial income and expenses -2.0 -2.9 -7.8
-------------------------------------------------------------------------------
Profit before taxes 9.8 9.9 57.1
Income taxes -2.3 -2.3 -10.7
-------------------------------------------------------------------------------
Profit for the period from
continuing operations 7.4 7.6 46.5
Profit for the period from
discontinued operations -0.1 -5.0 -258.8
-------------------------------------------------------------------------------
Profit for the period 7.3 2.6 -212.3
Other comprehensive income
Items which may be reclassified
subsequently to profit or loss:
Translation differences
recognised in comprehensive
income during the reporting
period 1.5 -17.4 -52.1
Translation differences
transferred to Profit for the
period from discontinued
operations - - 74.3
Cash flow hedge -0.4 -0.5 -1.4
Income tax relating to
other comprehensive income 0.1 0.6 0.3
-------------------------------------------------------------------------------
1.2 -17.4 21.1
Items which will not be
reclassified to profit or loss:
Actuarial gains/losses on
defined benefit plan - - -16.5
Income tax relating to
other comprehensive income - - 3.3
-------------------------------------------------------------------------------
- - -13.1
Total comprehensive income for
the period 8.5 -14.8 -204.3
Profit attributable to
-------------------------------------------------------------------------------
Parent company shareholders 7.3 2.6 -212.3
-------------------------------------------------------------------------------
Total comprehensive income
attributable to
-------------------------------------------------------------------------------
Parent company shareholders 8.5 -14.8 -204.3
-------------------------------------------------------------------------------
Earnings per share attributable
to parent company shareholders:
Basic earnings per share, EUR
-------------------------------------------------------------------------------
Continued operations 0.05 0.05 0.29
Discontinued operations -0.00 -0.03 -1.71
From profit of the year 0.04 0.02 -1.42
-------------------------------------------------------------------------------
Diluted earnings per share, EUR
-------------------------------------------------------------------------------
Continued operations 0.05 0.05 0.29
Discontinued operations -0.00 -0.03 -1.71
From profit of the year 0.04 0.02 -1.42
-------------------------------------------------------------------------------
(1) )The first quarter 2014 figures have been revised as a result of the sale
of the Russian business in December 2014 to reflect the classification of the
Russian business as a discontinued operation.
Consolidated Statement of
Financial Position (IFRS),
EUR million
ASSETS 31 Mar 2015 31 Mar 2014 (1)) 31 Dec 2014
-------------------------------------------------------------------------------
Non-current assets
Property, plant and equipment 73.8 92.0 75.2
Goodwill 253.7 365.5 250.9
Other intangible assets 61.6 69.8 61.3
Pension assets 0.0 9.3 0.0
Other non-current assets 0.0 0.0 0.0
Deferred tax assets 5.8 9.3 3.3
-------------------------------------------------------------------------------
Non-current assets total 395.0 545.9 390.8
Current assets
Inventories 194.3 357.0 185.0
Trade receivables 194.3 324.0 178.4
Other receivables 40.9 74.4 28.4
Cash and cash equivalents 137.1 88.0 91.5
-------------------------------------------------------------------------------
Current assets total 566.7 843.3 483.2
ASSETS TOTAL 961.6 1,389.2 874.0
-------------------------------------------------------------------------------
EQUITY AND LIABILITIES
-------------------------------------------------------------------------------
Equity
Share capital 36.2 36.2 36.2
Hedging reserve -1.7 -0.6 -1.3
Contingency fund 19.4 19.4 19.4
Invested unrestricted equity
reserve 75.0 1.1 1.1
Hybrid bond - 39.7 39.6
Other reserves 0.1 0.1 0.1
Translation differences -1.5 -42.3 -3.1
Retained earnings 25.1 249.4 21.6
-------------------------------------------------------------------------------
Equity attributable to the
parent company shareholders 152.7 303.0 113.6
Non-current liabilities
Deferred tax liabilities 13.8 17.3 12.7
Pension obligations 15.2 7.5 14.9
Borrowings 79.3 174.9 98.5
Other non-current liabilities 2.6 0.0 2.2
-------------------------------------------------------------------------------
Non-current liabilities total 110.9 199.7 128.3
Current liabilities
Trade payables 525.1 759.1 494.3
Provisions 1.9 1.5 0.6
Borrowings 120.6 85.6 95.4
Other current liabilities 50.5 40.3 41.8
-------------------------------------------------------------------------------
Current liabilities total 698.0 886.5 632.1
EQUITY AND LIABILITIES TOTAL 961.6 1,389.2 874.0
-------------------------------------------------------------------------------
(1)) Includes the assets and liabilities of the Russian businesses
sold in December 2014
Consolidated Statement
of Changes in Equity
(IFRS)
Equity attributable to the parent
company shareholders
Trans- Re-
lation tained
Share diffe- earn- Hybrid Equity
EUR million capital Funds rences ings bond total
-------------------------------------------------------------------------------
Equity
1 Jan 2014 36.2 20.4 -25.3 246.8 - 278.1
-------------------------------------------------------------------------------
Comprehensive income for
the period
Net profit for the
period - - - 2.6 - 2.6
Other comprehensive
income:
Cash flow hedge - -0.5 - - - -0.5
Income tax relating to
other comprehensive
income - 0.1 0.4 - - 0.6
Translation difference - -0.0 -17.4 - - -17.4
-------------------------------------------------------------------------------
Comprehensive income for
the period total - -0.4 -17.0 2.6 - -14.8
-------------------------------------------------------------------------------
Transactions with owners
Hybrid bond - - - - 39.7 39.7
Share-based payments - - - 0.0 - 0.0
-------------------------------------------------------------------------------
Transactions with owners
total - - - 0.0 39.7 39.7
-------------------------------------------------------------------------------
Equity
31 Mar 2014 36.2 20.0 -42.3 249.4 39.7 303.0
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Equity
1 Jan 2015 36.2 19.3 -3.1 21.6 39.6 113.6
-------------------------------------------------------------------------------
Comprehensive income for
the period
Net profit for the
period - - - 7.3 - 7.3
Other comprehensive
income:
Cash flow hedge - -0.4 - - - -0.4
Income tax relating to
other comprehensive
income - 0.1 - - - 0.1
Translation difference - - 1.5 -0.0 - 1.5
-------------------------------------------------------------------------------
Comprehensive income for
the period total - -0.3 1.5 7.3 - 8.5
-------------------------------------------------------------------------------
Transactions with owners
Share issue - 74.0 - - - 74.0
Hybrid bond paid
interest - - - -2.2 - -2.2
Hybrid bond redemption - - - -1.6 -39.6 -41.2
Share-based incentive - - - 0.0 - 0.0
Purchase of own shares - - - -0.0 - -0.0
-------------------------------------------------------------------------------
Transactions with owners
total - 74.0 - -3.8 -39.6 30.5
-------------------------------------------------------------------------------
Equity
31 Mar 2015 36.2 92.9 -1.5 25.1 - 152.7
-------------------------------------------------------------------------------
Condensed Consolidated Statement of Cash Flows (IFRS),
2015 2014 2014
EUR million (1)) 1-3 1-3 1- 12
-------------------------------------------------------------------------------
Operating profit 11.6 7.1 -42.4
Depreciation and amortisation 5.6 6.6 26.2
Impairment - - 71.1
Change in working capital -0.5 -32.5 -42.5
Cash flow from financial
items and taxes -1.3 -5.3 -13.5
Other adjustments -2.2 -1.7 -9.7
-------------------------------------------------------------------------------
Net cash flow from operating activities 13.3 -25.8 -10.8
Net cash flow from investing activities -3.9 -4.9 40.3
Net cash flow from financing activities 36.2 -17.4 -80.3
Net change in cash and cash equivalents 45.6 -48.0 -50.8
Cash and cash equivalents
at the beginning of the period 91.5 137.3 137.3
Foreign exchange rate differences 0.0 -1.3 5.0
Net change in cash and cash equivalents 45.6 -48.0 -50.8
-------------------------------------------------------------------------------
Cash and cash equivalents
at the end of the period 137.1 88.0 91.5
-------------------------------------------------------------------------------
(1) )Includes the net cash flow from the disposed Russian
businesses until 30 November 2014.
Notes to financial statements
Principal accounting policies as of 1 January 2015 (IFRS)
These financial statements release has been prepared in accordance with IFRS
standards (IAS 34). The accounting policies and calculation methods applied in
the interim report are the same as those in the 31 December 2014 annual
financial statements, excluding the standards and interpretations applied as of
1 January 2015 as presented below. However, the interim report does not include
all of the information and notes presented in the annual financial statements.
Consequently, the interim report should be read together with the company's
financial statements for 2014.
Results of the Russian businesses, sold in December 2014, are reported as
discontinued oprations separately from results from continuing operations in
January - March 2015. The comparative financial information for 2014 has been
revised to reflect the results for continuing operations. The consolidated
statement of financial position for comparative period 2014 includes the assets
and liabilities of discontinued operations. The consolidated statement of cash
flows for comparative period 2014 includes net cash flow of discontinued
operations.
The figures in the interim report have been rounded independently.
New standards or amendments to the existing ones that have been applied as of 1
January 2015:
* Amendment to IAS 19 Defined benefit plans
* Annual improvements in IFRS standards 2010-2012 and 2011-2013
The new standards have not had a material impact on the Group's financial
position.
The figures in this interim review are unaudited.
Earnings per share
2015 2014 2014
EUR million 1-3 1-3 1- 12
-------------------------------------------------------------------------------
Profit attributable to equity owners of the parent
from continuing operations 7.4 7.6 46.5
Accumulated interest on hybrid bond net of tax -0.2 -0.3 -1.9
-------------------------------------------------------------------------------
Adjusted profit for the period from continuing
operations 7.2 7.3 44.6
2015 2014 2014
EUR million 1-3 1-3 1- 12
-------------------------------------------------------------------------------
Profit incl. discontinued operations attributable to
equity owners of the parent 7.3 2.6 -212.3
Accumulated interest on hybrid bond net of tax -0.2 -0.3 -1.9
-------------------------------------------------------------------------------
Adjusted profit for the period including discontinued
operations 7.1 2.3 -214.2
Average number of outstanding shares (1000 shares)
Basic 158,504 151,142 151,130
Diluted 158,504 151,142 151,130
Earnings per share (EUR)
Basic
Continuing operations 0.05 0.05 0.29
Discontinuing operations -0.00 -0.03 -1.71
Total 0.04 0.02 -1.42
Diluted
Continuing operations 0.05 0.05 0.29
Discontinuing operations -0.00 -0.03 -1.71
Total 0.04 0.02 -1.42
Tangible and intangible assets
Changes in Property, Plant and Equipment, 2015 2014 2014
EUR million 1-3 1-3 1- 12
------------------------------------------------------------------------
Carrying amount at the beginning of the period 75.2 93.2 93.2
Increases through acquisitions of subsidiary shares - - 0.0
Increases 1.8 2.9 27.0
Decreases -0.1 -0.1 -13.2
Divestment of business - - -11.3
Reclassifications - 0.7 0.2
Other changes - 0.4 -
Depreciation, Continuing operations -3.7 -3.6 -15.0
Depreciation, Discontinued operations - -0.3 -1.3
Foreign exchange rate differences 0.6 -1.0 -4.4
------------------------------------------------------------------------
Carrying amount at the end of the period 73.8 92.0 75.2
------------------------------------------------------------------------
Changes in Intangible assets, 2015 2014 2014
EUR million 1-3 1-3 1- 12
------------------------------------------------------------------------
Carrying amount at the beginning of the period 312.3 451.0 451.0
Increases through acquisitions of subsidiary shares - - 0.2
Increases 1.5 2.0 6.8
Decreases - - -0.2
Divestment of business - - -24.5
Reclassifications - -0.7 -0.2
Amortisation, Continuing operations -1.9 -1.8 -7.2
Impairments and amortisation, Discontinued operations - -0.8 -73.8
Foreign exchange rate differences 3.4 -14.3 -39.8
------------------------------------------------------------------------
Carrying amount at the end of the period 315.3 435.3 312.3
------------------------------------------------------------------------
Derivatives
31 Mar 2015 Positive fair Negative fair Nominal values of
EUR million value value contracts
-------------------------------------------------------------------------
Derivatives recognised
as cash flow hedges
Interest rate swaps - 2.1 56.0
Derivatives measured at
fair value through profit and
loss
Foreign currency forward and
swap contracts - 1.3 108.5
-------------------------------------------------------------------------
31 Mar 2014 Positive fair Negative fair Nominal values of
EUR million value value contracts
-------------------------------------------------------------------------
Derivatives recognised
as cash flow hedges
Interest rate swaps - 0.8 44.7
Derivatives measured at
fair value through profit and
loss
Foreign currency forward and
swap contracts 0.7 - 115.2
-------------------------------------------------------------------------
Derivatives measured at fair value through profit and loss are mainly related to
hedging of group's internal transactions. Fair values of the derivatives have
been booked to balance sheet in gross amount as the derivatives contracts are
related to credit events and cannot be netted in financial statements. The group
has not given nor received collateral to/from derivatives counterparties.
Fair value hierarchy
EUR million
31 Mar 2015 Level 1 Level 2 Level 3 Total
-------------------------------------------------------------------------------
Assets
Derivatives measured at fair value through
profit and loss - 0.3 - 0.3
Liabilities
Derivatives designated as hedges - 2.1 - 2.1
Derivatives measured at fair value through
profit and loss - 1.6 - 1.6
Contingent consideration - - 15.1 15.1
-------------------------------------------------------------------------------
EUR million
31 Mar 2014 Level 1 Level 2 Level 3 Total
-------------------------------------------------------------------------------
Assets
Derivatives measured at fair value through
profit and loss - 0.9 - 0.9
Liabilities
Derivatives designated as hedges - 0.8 - 0.8
Derivatives measured at fair value through
profit and loss - 0.2 - 0.2
Contingent consideration - - 14.7 14.7
-------------------------------------------------------------------------------
Level 1: Quoted prices (unadjusted) in active markets for identical assets or
liabilities.
Level 2: Inputs other than quoted prices included within level 1 that are
observable for the asset or liability, either directly (i.e. as prices) or
indirectly (i.e. derived from prices).
Level 3: Inputs for the asset or liability that are not based on observable
market data (i.e. unobservable inputs).
Reconciliation of financial liabilities recognised at fair value through
profit and loss according to the level 3
EUR million
---------------------------------------
Book value 31 Dec 2014 14.7
---------------------------------------
Recognised in financial expenses 0.2
Translation differences 0.2
---------------------------------------
Book value 31 Mar 2015 15.1
---------------------------------------
Financial liabilities recognised at fair value through profit and loss (level
3) include estimated discounted fair value of a contingent consideration related
to the Medstop acquisition. Payment of the contingent consideration will be
based on 2015 EBITDA of Oriola-KD's combined Swedish retail businesses and will
be paid in first quarter of 2016. The fair value of the contingent consideration
has been calculated using discounted cash flow method. The discount rate used in
the valuation is determined using the weighted average cost of capital of the
Group.
Commitments and Contingent Liabilities
EUR million 31 Mar 2015 31 Mar 2014 31 Dec 2014
-------------------------------------------------------------------------------
Commitments for own liabilities
Guarantees on behalf of own companies 8.2 16.0 8.1
Guarantees on behalf of other companies 21.2 - 22.0
Mortgages on company assets 2.3 2.3 2.2
Other guarantees and liabilities 1.0 0.9 1.1
Accumulated interest on hybrid bond - 0.3 2.4
-------------------------------------------------------------------------------
Total 32.7 19.5 35.8
-------------------------------------------------------------------------------
Leasing liabilities (operating
liabilities) 0.8 2.8 0.8
Rent liabilities 44.4 72.7 44.3
Guarantees on behalf of other companies include parent company guarantees given
to third parties on behalf of sold Russian entities commercial agreements and
rent contracts. In accordance of framework agreement the buyer undertakes to
compensate Oriola-KD for any claim against the guarantees. In addition the
buyer's bank has given Oriola-KD in aggregate EUR 18.8 million counter-guarantee
mainly subject to parent company guarantees of the commercial agreements.
Majority of the guarantees on behalf of other companies will expire in 2015.
The most significant guarantees are bank guarantees against trade payables in
wholesale company in Sweden. In addition, Oriola-KD Corporation has granted
parent company guarantees of EUR 2.8 (24.4) million against subsidiaries' trade
payables and EUR 83.6 (151.9) million against Oriola-KD Holding Sverige AB's
external loan.
Provisions
On 31 March 2015 Oriola-KD had restructuring provisions totalling EUR 1.4 (1.5)
million related to Finnish pharmaceutical wholesale business, Consumer Health
and the group administration and restructuring costs incurred by Pharmaceutical
Trade Sweden in connection with the integration of the Medstop acquisition. In
addition, group items include a provision of EUR 0.5 (-) million related to the
sale of Russian businesses included within profit for the period from
discontinued operations.
Related parties
Related parties in the Oriola-KD Group are deemed to comprise the members of the
Board of Directors and the President and CEO of Oriola-KD Corporation, the other
members of the Group Management Team of the Oriola-KD Group, the immediate
family of the aforementioned persons, the companies controlled by the
aforementioned persons, and the Oriola Pension Fund. The Group has no
significant business transactions with related parties, except for pension
expenses arising from defined benefit plans with the Oriola Pension Fund.
Segment information( 1)
2015 2014 2014
Net Sales, EUR million 1-3 1-3 1- 12
----------------------------------------------------
Pharmaceutical Trade
Finland and Baltics 104.7 100.8 435.9
Pharmaceutical Trade Sweden 306.6 298.5 1,176.4
Net sales to other segments -0.0 -0.0 -0.0
----------------------------------------------------
Total 411.3 399.3 1,612.3
2015 2014 2014
Operating Profit, EUR million 1-3 1-3 1- 12
----------------------------------------------------
Pharmaceutical Trade
Finland and Baltics 3.7 4.8 19.2
Pharmaceutical Trade Sweden 10.0 9.4 50.5
Group Administration and
Others -2.0 -1.3 -4.6
----------------------------------------------------
Total 11.7 12.8 65.0
Operating Profit excl. Non-
recurring items, 2015 2014 2014
EUR million 1-3 1-3 1- 12
----------------------------------------------------
Pharmaceutical Trade
Finland and Baltics 4.6 4.8 19.6
Pharmaceutical Trade Sweden 10.0 10.0 44.0
Group Administration and
Others -1.5 -1.3 -4.5
----------------------------------------------------
Operating Profit excl. non-
recurring items 13.1 13.5 59.1
----------------------------------------------------
Non-recurring items -1.4 -0.6 5.9
----------------------------------------------------
Total 11.7 12.8 65.0
2015 2014 2014 2014 2014
Quarterly Net Sales, EUR
million 1-3 10-12 7-9 4-6 1-3
-------------------------------------------------------------------------------
Pharmaceutical Trade
Finland and Baltics 104.7 119.6 108.5 107.0 100.8
Pharmaceutical Trade Sweden 306.6 298.1 281.3 298.5 298.5
Net sales to other segments -0.0 0.0 -0.0 -0.0 -0.0
-------------------------------------------------------------------------------
Total 411.3 417.7 389.8 405.5 399.3
2015 2014 2014 2014 2014
Quarterly Operating Profit,
EUR million 1-3 10-12 7-9 4-6 1-3
-------------------------------------------------------------------------------
Pharmaceutical Trade
Finland and Baltics 3.7 4.4 5.5 4.4 4.8
Pharmaceutical Trade Sweden 10.0 17.7 12.3 11.0 9.4
Group Administration and
Others -2.0 -0.1 -1.6 -1.5 -1.3
-------------------------------------------------------------------------------
Total 11.7 22.1 16.3 13.8 12.8
Quarterly Operating Profit, 2015 2014 2014 2014 2014
excl. non-recurring items, EUR
million 1-3 10-12 7-9 4-6 1-3
-------------------------------------------------------------------------------
Pharmaceutical Trade
Finland and Baltics 4.6 4.9 5.5 4.4 4.8
Pharmaceutical Trade Sweden 10.0 10.2 12.4 11.3 10.0
Group Administration and
Others -1.5 -0.0 -1.6 -1.5 -1.3
-------------------------------------------------------------------------------
Operating Profit excl. non-
recurring items 13.1 15.1 16.3 14.2 13.5
-------------------------------------------------------------------------------
Non-recurring items -1.4 6.9 -0.1 -0.3 -0.6
-------------------------------------------------------------------------------
Total 11.7 22.1 16.3 13.8 12.8
2015 2014 2014
Net Sales by Market, EUR
million 1-3 1-3 1- 12
----------------------------------------------------
Finland 91.1 89.2 388.3
Sweden 291.0 284.4 1,114.8
Baltic countries 11.7 10.9 43.5
Other countries 17.5 14.8 65.7
----------------------------------------------------
Total 411.3 399.3 1,612.3
2015 2014 2014 2014 2014
Quarterly Net Sales by Market,
EUR million 1-3 10-12 7-9 4-6 1-3
-------------------------------------------------------------------------------
Finland 91.1 106.1 97.1 95.9 89.2
Sweden 291.0 280.9 265.8 283.7 284.4
Baltic countries 11.7 11.8 11.1 9.8 10.9
Other countries 17.5 19.0 15.9 16.1 14.8
-------------------------------------------------------------------------------
Total 411.3 417.7 389.8 405.5 399.3
(1) )The first quarter 2014 figures have been revised as a result of the
sale of the Russian business in December 2014. Russian business are
classified as a discontinued operation.
Espoo, 23 April 2015
Board of Directors of Oriola-KD Corporation
Further information:
Eero Hautaniemi
President and CEO
tel. +358 (0)10 429 2109
e-mail: eero.hautaniemi@oriola-kd.com
Distribution:
NASDAQ OMX Helsinki Ltd
Key media
Released by:
Oriola-KD Corporation
Corporate Communications
Orionintie 5
02200 Espoo
www.oriola-kd.com
[HUG#1913539]